ArticleEuropean journal of hospital pharmacy : science and practice2019
Association between allopurinol use and hepatocellular carcinoma in a case-control study in Taiwan.
Article in European journal of hospital pharmacy : science and practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Association between allopurinol and hepatocellular carcinoma: analysis of genetic risk and patient survival.Discover oncology · 2025Article
- Evaluating the association between avascular necrosis of femoral head and oral corticosteroids use in Taiwan.Medicine · 2020Observational
- Association between Parkinson's disease and proton pump inhibitors therapy in older people.BioMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesLittle is known about the role of allopurinol use on the risk of hepatocellular carcinoma (HCC). The study aimed to examine the association between allopurinol use and HCC in Taiwan.
methodsUsing the database from the Taiwan National Health Insurance Program, we designed a case-control study that consisted of 4901 subjects aged 20-84 years with newly diagnosed HCC as the case group, and 4901 subjects aged 20-84 years without HCC as the control group, from 2000 to 2013. Ever use of allopurinol was defined as a subject who had at least a prescription for allopurinol before the index date. Never use was defined as a subject who never had a prescription for allopurinol before the index date. The OR and 95% CI for HCC associated with allopurinol use was measured by the multivariable logistic regression model.
resultsAfter adjustment for confounding factors, the adjusted OR of HCC was 0.93 (95% CI 0.81 to 1.07) for subjects with ever use of allopurinol, compared with never use. The adjusted OR of HCC was 1.01 for subjects with increasing cumulative duration of allopurinol use for every 1 year (95% CI 0.92 to 1.12), compared with never use. The adjusted OR of HCC was 0.99 for subjects with increasing cumulative dosage of allopurinol use for every 50 mg (95% CI 0.94 to 1.05), compared with never use.
conclusionsNo statistical association can be detected between allopurinol use and HCC risk in Taiwan. There are no duration-dependent and dosage-dependent effects of allopurinol use on the risk of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.